Breaking News, Collaborations & Alliances

Fusion Pharma, AstraZeneca Enter Radiopharmaceuticals Alliance

Leverages Fusion's Targeted Alpha Therapies platform and radiopharmaceuticals expertise and AstraZeneca's portfolio of antibodies and cancer therapies.

By: Contract Pharma

Contract Pharma Staff

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on radiopharmaceuticals as precision medicines, has entered a collaboration with AstraZeneca to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therape...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters